About Us

Empowered by AI,
Designed for Humanity.

AI x HUMAN-RELEVANT BIOLOGY

Human-Centered AI for
Drug Discovery

Combines AI with human-relevant biology to accelerate drug discovery—grounded in ethics, usability, and real-world impact.

AI-POWERED

Microphysiological Platform

Organ-on-chip + AI agents to deliver faster, more reliable preclinical insights.

3RS PRINCIPLE

Replace, Reduce,
and Refine

Driven by the 3Rs, our global team is redefining drug development with scalable, animal-free solutions.

MEET THEFOUNDER

Guan Yu Chen, Ph.D.Founder & CEO

“

No Animals, No Delays, Just Human Data'
is the future we envision.'No Animals, No Delays,
Just Human Data'
is the future we envision.

Dr.Guan-Yu Chen, founder of Anivance AI, established the Anivance AI in 2024 and has since led his team in developing a new generation of organ-on-chip systems and AI-driven biomedical analysis platforms.
The team is dedicated to advancing precision medicine and laboratory automation, working in collaboration with global pharmaceutical companies and medical institutions.

Guan has published more than 50 peer-reviewed international journal articles throughout his research career and has led over 30 major research projects funded by the National Science and Technology Council, the National Health Research Institutes, the Council of Agriculture, and the Ministry of Environment. He also holds more than 25 patents across the United States, the European Union and Taiwan.

He has received numerous distinguished honors, including the Asia Young Researcher Award from the Lush Prize, the Outstanding Entrepreneurship Award, the 61st Ten Outstanding Young Persons Award in Taiwan, the Moderna Taiwan mRNA Pioneer Innovation Award, and the 20th National Innovation Award, among other recognitions.